AVDL

Avadel Pharmaceuticals plc (AVDL) | Rumor.io

Avadel Pharmaceuticals

AVDL

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)87%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about AVDL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 12

Avadel Pharmaceuticals plc ($AVDL) has been acquired by Alkermes, with 4 active clinical trials ongoing.
Avadel has requested a halt in trading and filed Form 25 to delist from Nasdaq, triggering a sector rotation play.
The delisting is expected to cause a major volume spike, with a high-risk move strategy recommended.

Generated by AI

Sentiment

Of the messages about AVDL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	86.54% +3.77
Bearish	—	—	—	13.46% -3.77

Bullish· Oct 22

$AVDL's buyout provides a clear path forward for the company, resolving costly litigation and giving them a significant non-dilutive cash boost.
Avadel Pharmaceuticals' revenue has increased 64.2% year-over-year, achieving net profit, and the company's second-quarter 2025 financial report was impressive.
The buyout of $AVDL offers a significant gain of 76% from its 2024 close, and insiders with excellent records, including the CEO and CFO, have recently made purchases.

Bearish· Oct 5

$AVDL's price drop was likely due to institutional investors selling out, which triggered short covering and then short selling.
The stock's high institutional hold and subsequent price pump may have led to retail investors buying in, only to be unloaded by institutional sellers.
The stock's dilution could lead to a further price drop, as institutional investors may continue to sell out and retail investors may be left holding the bag.

Generated by AI

Topics

Of the messages about AVDL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	7.65%
Announcements	—	—	—	72.45%
Controversies	—	—	—	5%
Earnings	—	—	—	2.25%
Macro	—	—	—	1.86%
Technical Analysis	—	—	—	10.78%

Earnings· Nov 8

Avadel Pharmaceuticals PLC ($AVDL) reports Q3 earnings of 9c EPS and $39.67M revenue.
$AVDL beats EPS estimates by $0.10 and revenue estimates by $1.87M.
Avadel Pharmaceuticals updates FY17 guidance to $0.25-0.35 EPS and $165-175 million revenue.

Announcements· Nov 19

Alkermes has increased its bid for Avadel Pharmaceuticals to $22.50 per share, offering $21 in cash and up to $1.50 via a CVR linked to FDA approval of LUMRYZ for idiopathic hypersomnia by the end of 2028.
The deal values Avadel at about $2.37 billion and includes an upfront cash payment of $21 plus a potential $1.50 per share in a contingent value right tied to US FDA approval of Avadel's Lumryz.
Avadel has accepted Alkermes' revised $2.37B counteroffer, besting Lundbeck's bid, with the transaction expected to close in the first quarter of 2026.

Technical Analysis· May 27

$AVDL has gapped more than 20% 4 times in the last 5 years, with an average spike of 9% from open before turning red.
The stock has formed a cup and handle pattern on both hourly and 15-minute charts, with potential targets at $3.50.
The MACD indicator has crossed over, and the RSI is at 44, indicating a potential reversal and a possible move back up to $2.80 or higher.

Generated by AI

Community

Of the messages about AVDL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	53.52%
Newcomers	—	—	—	46.48%

Regulars· Nov 14

Avadel Pharmaceuticals ($AVDL) has received an unsolicited takeover bid from Lundbeck worth up to $23 per share.
The bid includes 21 in cash plus up to 2 in CVRs tied to LUMRYZ and valyloxybate sales milestones, surpassing its existing deal with Alkermes.
Regulars expect a bidding war, with some estimating the proposed deal should trade at 20.9-21.15ish, and others seeing this as another bullish sign for biotech.

Newcomers· Nov 19

Alkermes ($ALKS) has increased its offer to acquire Avadel Pharmaceuticals ($AVDL) to $22.50 per share, including $21 in cash and a potential $1.50 via a contingent value right tied to FDA approval of Avadel's Lumryz by the end of 2028.
The deal values Avadel at about $2.37 billion, and could be worth up to $2.4 billion if Lundbeck's bid is considered superior.
Avadel Pharmaceuticals shares have traded higher after Alkermes increased the buyout offer, but have since given up their prior gains, and the stock is currently trading at $25.

Generated by AI

Also Discussed

Investors talking about AVDL also mention

#	Name	Attention
1	Jazz Pharmaceuticals plcJAZZ	0%0
2	Beyond Air, Inc.XAIR	0%0
3	Axsome Therapeutics IncAXSM	0.01%0
4	ITCI - Intra-Cellular Therapies, Inc.	——
5	TG Therapeutics Inc.TGTX	0.01%+0
6	Verrica Pharmaceuticals Inc.VRCA	0%0
7	OPTN - OptiNose, Inc.	——
8	DAWN - Day One Biopharmaceuticals, Inc.	——
9	CEL-SCI CorporationCVM	0%0
10	Travere Therapeutics Inc.TVTX	0%0